Allogeneic cell therapy manufacturing: process development technologies and facility design options
Introduction: Currently, promising outcomes from clinical trials of allogeneic cells, especially
allogeneic mesenchymal stromal cells, fibroblasts, keratinocytes, and human cardiac stem …
allogeneic mesenchymal stromal cells, fibroblasts, keratinocytes, and human cardiac stem …
[PDF][PDF] Allogeneic cell therapy manufacturing: process development technologies and facility design options
S Abbasalizadeh, M Pakzad, JMS Cabral… - 2017 - researchgate.net
Introduction: Currently, promising outcomes from clinical trials of allogeneic cells, especially
allogeneic mesenchymal stromal cells, fibroblasts, keratinocytes, and human cardiac stem …
allogeneic mesenchymal stromal cells, fibroblasts, keratinocytes, and human cardiac stem …
[引用][C] Allogeneic cell therapy manufacturing: process development technologies and facility design options
S Abbasalizadeh, M Pakzad, JMS Cabral… - Expert Opinion on …, 2017 - cir.nii.ac.jp
Allogeneic cell therapy manufacturing: process development technologies and facility design
options | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
options | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
Allogeneic cell therapy manufacturing: process development technologies and facility design options
S Abbasalizadeh, M Pakzad… - Expert opinion on …, 2017 - pubmed.ncbi.nlm.nih.gov
Currently, promising outcomes from clinical trials of allogeneic cells, especially allogeneic
mesenchymal stromal cells, fibroblasts, keratinocytes, and human cardiac stem cells, have …
mesenchymal stromal cells, fibroblasts, keratinocytes, and human cardiac stem cells, have …